Latest Conference Articles

June 8th 2022, 4:00pm

ASCO Annual Meeting

Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.

June 8th 2022, 1:04pm

ASCO Annual Meeting

Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.

June 8th 2022, 12:32pm

ASCO Annual Meeting

Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.

June 7th 2022, 10:44pm

ASCO Annual Meeting

Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.

June 7th 2022, 10:00pm

ASCO Annual Meeting

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

June 7th 2022, 9:05pm

ASCO Annual Meeting

Larotrectinib demonstrated longer overall survival compared with standard-of-care therapy in patients with TRK fusion–positive cancer.

June 7th 2022, 9:02pm

ASCO Annual Meeting

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

June 7th 2022, 8:26pm

ASCO Annual Meeting

Seribantumab was found to produce encouraging overall response rates with acceptable tolerability when used as a monotherapy in patients with solid tumors harboring NRG1 fusions.

June 7th 2022, 8:15pm

ASCO Annual Meeting

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

June 7th 2022, 7:35pm

ASCO Annual Meeting

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

June 7th 2022, 7:20pm

ASCO Annual Meeting

Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.

June 7th 2022, 6:30pm

ASCO Annual Meeting

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

June 7th 2022, 4:50pm

ASCO Annual Meeting

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

June 7th 2022, 4:23pm

ASCO Annual Meeting

The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.

June 7th 2022, 3:25pm

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

June 7th 2022, 3:11pm

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

June 7th 2022, 3:10pm

ASCO Annual Meeting

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

June 7th 2022, 2:35pm

ASCO Annual Meeting

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

June 7th 2022, 2:34pm

ASCO Annual Meeting

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

June 7th 2022, 2:15pm

ASCO Annual Meeting

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.